Tetraphase Pharmaceuticals Inc.’s lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
Eisai’s Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Genentech announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.
As part of the company’s fourth-quarter 2017 earnings report, Paris-based Sanofi released a pipeline update showing it plans to halt several mid-stage drug programs.
Biogen Inc. will stop testing the company’s established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study.
Women who develop high blood pressure during pregnancy may have the condition reappear within a year of delivery, and many of them may go undiagnosed because the problem only surfaces at night, a new study suggests.
Use of Xtandi in early-stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone.
Genentech’s Tecentriq and Avastin combo met co-primary endpoint in late-stage study for advanced kidney cancer
Genentech announced results from the positive Phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.
Shares of Bristol-Myers Squibb climbed after announcing its anticipated Phase III CheckMate-227 study met its endpoints of progression-free survival as a first-line lung cancer treatment.